Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 261 to 270 of 857 total matches.

Safe Needles

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
FOR ONLINE USERS SAFE NEEDLES Accidental needlesticks can lead to infection with hepatitis viruses, human ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Med Lett Drugs Ther. 1991 Apr 5;33(841):32 |  Show IntroductionHide Introduction

Telbivudine (Tyzeka) for Chronic Hepatitis B

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007  (Issue 1253)
chronic hepatitis B virus (HBV) infection. It is the fourth oral drug marketed for this indication ...
The FDA has approved the nucleoside analog telbivudine (Tyzeka - Novartis/Idenix) for treatment of patients ≥16 years old with active chronic hepatitis B virus (HBV) infection. It is the fourth oral drug marketed for this indication in the US.
Med Lett Drugs Ther. 2007 Jan 29;49(1253):11-2 |  Show IntroductionHide Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
However, there is a potential risk of foodborne HAV infection even in countries with low endemicity ...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine...
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 |  Show IntroductionHide Introduction

Adalimumab (Humira) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2003  (Issue 1153)
. Injection site pain and local reactions can occur. Upper respiratory tract infections, nausea, flu-like ...
Adalimumab (Humira - Abbott), a tumor necrosis factor alpha (TNF-α) inhibitor, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA). A genetically engineered human IgG1 monoclonal antibody, adalimumab is approved for subcutaneous (SC) injection in adults who have failed at least one disease-modifying anti-rheumatic drug (DMARD), for use either alone or with other DMARDs such as methotrexate (Rheumatrex, and others). Two other TNF-α antagonists, etanercept (Enbrel) and infliximab (Remicade), are already on the market for treatment of RA (Treatment...
Med Lett Drugs Ther. 2003 Mar 31;45(1153):25-7 |  Show IntroductionHide Introduction

Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004  (Issue 1185)
tinea pedis infection. It has been available in Europe for many years. PHARMACOLOGY AND SPECTRUM — Like ...
Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Jun 21;46(1185):50-2 |  Show IntroductionHide Introduction

Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
Pronunciation Key Shingrix: shing' riks HERPES ZOSTER – Following primary infection, VZV persists in a latent ...
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine (Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes zoster vaccine to be approved in the US; Zostavax, a live-attenuated VZV vaccine approved for the same indication, has been available since 2006.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):195-6 |  Show IntroductionHide Introduction

Baricitinib (Olumiant) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
of baricitinib 2 mg in clinical trials were upper respiratory tract infection (16%) and nausea (3%). Serious ...
The FDA has approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly) for oral treatment of adults with moderately to severely active rheumatoid arthritis (RA) that has not responded adequately to one or more tumor necrosis factor (TNF) inhibitors. Baricitinib is the second JAK inhibitor to be approved for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) was the first.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):120-1 |  Show IntroductionHide Introduction

Lenacapavir (Sunlenca) for Multidrug-Resistant HIV

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 1675)
drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced adults ...
The FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Sunlenca – Gilead) for use with other antiretroviral drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced adults whose current regimen is failing. Lenacapavir is the third drug to be approved exclusively for treatment of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the orally administered HIV-1 gp120-directed attachment inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70   doi:10.58347/tml.2023.1675c |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
fatal infection caused by the JC virus, can occur in patients treated with natalizumab; those who ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Pegademase

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 1990  (Issue 827)
infections. Given alone, the enzyme is eliminated too rapidly to be helpful, but covalent attachment of PEG ...
Pegademase (Adagen - Enzon), bovine adenosine deaminase (ADA) conjugated with polyethylene glycol (PEG), was recently approved by the US Food and Drug Administration as an 'orphan drug' for treatment of severe combined immunodeficiency disease (SCID). SCID due to inherited deficiency of ADA occurs in less than one per million births; until recently, without extraordinary isolation measures, it was usually fatal before the age of two.
Med Lett Drugs Ther. 1990 Sep 21;32(827):87-8 |  Show IntroductionHide Introduction